Search

Objectives: Unused medications have not only caused wastage, but improper disposal of unwanted medicines also has a negative impact on the environment and public health. The aim of this study was to study the public's knowledge, awareness and practice of disposing of unwanted or unused medicines in Malaysia. Methods: This was a descriptive, cross‐sectional survey conducted across Malaysia among the general public using a pre‐validated questionnaire. A non‐probability convenience sampling method was used for data collection. The approval of the study was obtained from ethics committee, and written consent was acquired from the participants prior to the data collection. Key findings: The study involved 483 subjects. Only 13.8% of the respondents scored >80% in their knowledge of the proper disposal methods. Majority of the respondents were very mindful of their responsibility towards the environment (95.3%), living species on earth (94.6%) and family members (96.7%) attributable to unintentional harmful exposure to unused medicines. Respondents admitted that they have unused medicines because they stop taking the medicines when they feel better (76.9%), doctor has changed their treatment (50.3%), experienced unwanted side effects (49%), did not take the medicines as instructed/prescribed (47.2%) and did not feel better after taking the medicines (46%). A substantial correlation has been established between the knowledge of improper disposal methods and their current practices. Conclusions: This finding suggested that a lack of knowledge and awareness is a major factor in the improper disposal of unused medicines. Therefore, an urgent need to increase public awareness through educational campaigns and Medication Return Program should be promoted more effectively. [ABSTRACT FROM AUTHOR]

Abstract: Objective: Hepatitis C is a chronic infectious liver disease that can lead to cirrhosis, liver cancer and liver failure. This study aimed to estimate the healthcare cost of treating chronic hepatitis C virus (HCV) from the perspective of Ministry of Health hospitals in Malaysia. Methods: The cost analysis study was conducted from the healthcare provider's perspective. Healthcare sector resource utilisations for managing patients with chronic hepatitis C were obtained from a retrospective cohort study of patients with hepatitis C at Sultanah Bahiyah Hospital, Malaysia, between December 2008 and 2014. These utilisations were organised by disease stage. When no patients were available for a specific stage, resource utilisations were estimated using expert opinions collected through iterative structured interviews with two gastroenterologists. Key findings: There were 112 patients included in the final analysis. Ninety‐one per cent of these were male, and patients had a mean age of 45.8 (SE 1.1) years. The mean (SE) annual total cost for ‘mild and moderate chronic HCV’ was GBP 338.08 (58.95), that for ‘compensated cirrhosis chronic HCV’ was GBP 493.39 (162.57), that for ‘recovered, no HCV, history of mild fibrosis’ was GBP 259.73 (30.79), that for ‘recovered, no HCV, history of moderate fibrosis’ was GBP 257.09 (31.10), that for ‘recovered, no HCV, history of severe fibrosis’ was GBP 359.92, that for ‘decompensated cirrhosis’ was GBP 512.89 (214.12), and that for ‘hepatocellular carcinoma’ was GBP 426.08. Conclusions: Chronic HCV infection is generally a progressively expensive condition. [ABSTRACT FROM AUTHOR]